Changing Landscape of Diagnosis and Personalized Therapies for Acute Myeloid Leukemia – Enduring Webcast

Description

Program Description

---

AML is the most common acute leukemia, with significant chromosomal translocations and mutations in the genes involved in hematopoietic proliferation and differentiation, accumulating poorly differentiated myeloid cells. AML is a highly heterogeneous disease with favorable, intermediate, and adverse-risk groups based on their cytogenetic profile. The prognosis within these categories varies widely. Identifying recurrent genetic mutations, such as FLT3-ITD, NMP1, and CEBPA, has helped refine individual prognosis and guide management. The selection of patients based on cytogenetic, molecular genetic markers, and human leukocyte antigen (HLA) testing and treatment with CPX-351, IDH1/2, FLT3, BCl-2, CD33, and Hedgehog pathway targeted agents, and HCT is the focus of the virtual live and enduring webcast.

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, and other healthcare professionals caring for patients with acute myeloid leukemia.

Commercial Supporter

---

This activity is supported by an educational grant from Daiichi Sankyo, Inc.